Large-scale trial confirms Genomic Health's Oncotype DX in determining breast cancer risk in women

By Lisa Kerner

Erie, Pa., May 23 - The Journal of Clinical Oncology published results of a large-scale trial conducted with the National Surgical Adjuvant Breast and Bowel Project confirming Genomic Health, Inc.'s Oncotype DX gene panel.

Oncotype DX, which uses RNA analysis of tumor tissues to measure the expression profile of a panel of 21 genes, quantifies the risk of breast cancer recurrence and predicts the likelihood of response to chemotherapy in a large portion of women with early-stage breast cancer, according to a company news release.

The journal published the study online to coincide with the launch of Tailorx (Trial Assigning Individualized Options for Treatment [Rx]), an individualized treatment trial using Oncotype DX to identify and assign treatment to more than 10,000 women from 900 sites in the United States and Canada.

Treatment will range from chemotherapy with hormonal therapy to hormonal therapy alone.

"With Tailorx, we hope to gain a better understanding of the effects of chemotherapy for those patients with midrange scores, building upon what we've already learned in an effort to individualize treatment for all women with early-stage breast cancer," director of the NSABP Division of Pathology Soonmyung Paik said in the release.

Genomic Health is a life science company located in Redwood City, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.